Conferences
ASCO GU 2025: Overcoming Challenges of Antibody Drug Conjugate Toxicity in Bladder Cancer
February 18, 2025
ASCO GU 2025: Targeting Bladder Cancer with Antibody Drug Conjugates
February 18, 2025
ASCO GU 2025: Primary Retroperitoneal Lymph Node Dissection in Stage II Seminoma: Management Strategies and Current Controversies
February 18, 2025
ASCO GU 2025: High-Dose Chemotherapy in Testicular Cancer: Current Evidence and Clinical Indications
February 18, 2025
ASCO GU 2025: HER2 Antibody Drug Conjugate Therapy: A New Frontier in Bladder Cancer
February 18, 2025
ASCO GU 2025: Better Together? Exploring Novel Drug Combinations with Antibody Drug Conjugates
February 18, 2025
ASCO GU 2025: Beyond PSMA-Targeted Agents for Advanced Disease
February 18, 2025
ASCO GU 2025: A Prospective Trial of a Structured Exercise Program to Lessen Fatigue in Patients with Advanced Prostate Cancer Undergoing ADT
February 18, 2025
ASCO GU 2025: Radium-223 Without ADT in Patients with Biochemically Recurrent Prostate Cancer and PET Findings in the Bones
February 18, 2025
ASCO GU 2025: Impact of Baseline PSMA PET in Patients with mCRPC Starting First-Line Androgen Receptor Signaling Inhibitor Therapy
February 18, 2025
ASCO GU 2025: The Future of Biomarkers in Renal Cell Carcinoma
February 18, 2025
ASCO GU 2025: SOAR: Phase II Trial of Image-Guided Oligometastatectomy and Radiation Therapy in Recurrent Prostate Cancer
February 18, 2025
ASCO GU 2025: Adjuvant Therapy in Renal Cell Cancer: A Practical Guide
February 18, 2025